Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Multiple analysts have issued price targets for $REGN recently. We have seen 17 analysts offer price targets for $REGN in the last 6 months, with a median target of ...

Fintel reports that on November 24, 2025, HSBC initiated coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Buy ...

Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being ...

Regeneron Pharmaceuticals (REGN) shares have been in focus recently, attracting investor interest thanks to their steady revenue and net income growth over the past year. The stock has gained 16% in ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

Members of Congress have traded $REGN stock 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales. Here’s a breakdown of recent ...